These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 28963831)

  • 1. [Neprilysin inhibition and chronic kidney disease].
    Di Lullo L; Ronco C; Bellasi A; Cozzolino M; Floccari F; Barbera V; Verdesca S; Rivera R; De Pascalis A; Mudoni A; Santoro A
    G Ital Nefrol; 2017 Sep; 34(5):102-112. PubMed ID: 28963831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neprilysin inhibition in chronic kidney disease.
    Judge P; Haynes R; Landray MJ; Baigent C
    Nephrol Dial Transplant; 2015 May; 30(5):738-43. PubMed ID: 25140014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TaleNeprilysin and Neprilysin inhibition in chronic kidney disease.
    Judge PK; Haynes R
    Curr Opin Nephrol Hypertens; 2021 Jan; 30(1):123-130. PubMed ID: 33148948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacubitril/Valsartan (LCZ696) in Heart Failure.
    Khder Y; Shi V; McMurray JJV; Lefkowitz MP
    Handb Exp Pharmacol; 2017; 243():133-165. PubMed ID: 28004291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan.
    Chrysant SG
    J Am Soc Hypertens; 2017 Jul; 11(7):461-468. PubMed ID: 28652105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.
    Vardeny O; Miller R; Solomon SD
    JACC Heart Fail; 2014 Dec; 2(6):663-70. PubMed ID: 25306450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Combination of Valsartan and Sacubitril in the Treatment of Hypertension and Heart Failure - an Update.
    Nielsen PM; Grimm D; Wehland M; Simonsen U; Krüger M
    Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):9-18. PubMed ID: 28944989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.
    Lillyblad MP
    Ann Pharmacother; 2015 Nov; 49(11):1237-51. PubMed ID: 26175499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and renal complications?
    Malek V; Gaikwad AB
    Biomed Pharmacother; 2017 Jun; 90():752-759. PubMed ID: 28419972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.
    Jhund PS; McMurray JJ
    Heart; 2016 Sep; 102(17):1342-7. PubMed ID: 27207980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.
    Ansara AJ; Kolanczyk DM; Koehler JM
    J Clin Pharm Ther; 2016 Apr; 41(2):119-27. PubMed ID: 26992459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure.
    Macdonald PS
    Clin Ther; 2015 Oct; 37(10):2199-205. PubMed ID: 26386501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LCZ696 : a new paradigm for the treatment of heart failure?
    Minguet J; Sutton G; Ferrero C; Gomez T; Bramlage P
    Expert Opin Pharmacother; 2015 Feb; 16(3):435-46. PubMed ID: 25597387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focus on the Novel Cardiovascular Drug LZC696: from Evidence to Clinical Consideration.
    Lin LM; Wu Y; Wu MF; Lin JX
    Cardiovasc Drugs Ther; 2016 Dec; 30(6):623-633. PubMed ID: 27858191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan.
    Liu RC
    Am J Cardiovasc Drugs; 2018 Dec; 18(6):473-482. PubMed ID: 29850980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial.
    Packer M; Claggett B; Lefkowitz MP; McMurray JJV; Rouleau JL; Solomon SD; Zile MR
    Lancet Diabetes Endocrinol; 2018 Jul; 6(7):547-554. PubMed ID: 29661699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sacubitril/Valsartan: A Novel Cardiovascular Combination Agent.
    Sible AM; Nawarskas JJ; Alajajian D; Anderson JR
    Cardiol Rev; 2016; 24(1):41-7. PubMed ID: 26466333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances.
    McMurray JJ
    Eur J Heart Fail; 2015 Mar; 17(3):242-7. PubMed ID: 25756942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure.
    Andersen MB; Simonsen U; Wehland M; Pietsch J; Grimm D
    Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):14-22. PubMed ID: 26280447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.